Laparoscopic versus open left hemihepatectomy for hepatocellular carcinoma: a propensity score matching analysis

Despite the increasing application of laparoscopic hepatectomy (LH) for hepatocellular carcinoma (HCC), laparoscopic left hemihepatectomy (LLH) remains a relatively rare surgery and comparison of perioperative and oncological outcomes between LLH and open left hemihepatectomy (OLH) is lacking. A tot...

Full description

Saved in:
Bibliographic Details
Published inTranslational cancer research Vol. 9; no. 9; pp. 5484 - 5492
Main Authors Yi, Yong, Weng, Jialei, Zhou, Chenhao, Liu, Gao, Ren, Ning
Format Journal Article
LanguageEnglish
Published China AME Publishing Company 01.09.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Despite the increasing application of laparoscopic hepatectomy (LH) for hepatocellular carcinoma (HCC), laparoscopic left hemihepatectomy (LLH) remains a relatively rare surgery and comparison of perioperative and oncological outcomes between LLH and open left hemihepatectomy (OLH) is lacking. A total of 276 HCC patients who underwent either LLH or OLH between January 2008 and November 2019 were enrolled in this retrospective observational study and a 1:2 propensity score matching (PSM) was performed between LLH and OLH groups. Patients in LLH group had smaller tumor size (P=0.001) and earlier TNM staging (P=0.022) before matching. Despite the similar transfusion rate after matching, patients undergoing LLH (n=27) experienced less intraoperative blood loss (100.0 versus 200.0 mL; P=0.034) and application of hepatic portal occlusion (11.1% versus 63.5%; P<0.001) compared to those in OLH group (n=52). There were no statistical differences of resection margin and incidence of complications between the groups. The overall survival (OS) and disease-free survival (DFS) of patients in LLH group were comparable to OLH group (3-year OS rate: 75.0% versus 84.9%; 1-year DFS rate: 92.3% versus 92.2%). LLH may be a feasible and safe alternative to OLH for selected HCC cases, providing potential short-term benefits without compromising oncologic adequacy and prognosis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
Contributions: (I) Conception and design: N Ren; Y Yi; (II) Administrative support: N Ren; (III) Provision of study materials or patients: Y Yi; C Zhou; (IV) Collection and assembly of data: J Weng; G Liu; (V) Data analysis and interpretation: J Weng; C Zhou; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
ISSN:2218-676X
2219-6803
DOI:10.21037/tcr-20-1573